The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: a novel series of CRF-1 receptor antagonists.
The design, synthesis and structure-activity relationships of a novel series of CRF-1 receptor antagonist, the 1-aryl-4-alkylaminoisoquinolines, is described. The effects of substitution on the aromatic ring, the amino group and the isoquinoline core on CRF-1 receptor binding were investigated.
Yoon
Taeyoung
T
Neurogen Corporation, 35 North East Industrial Road, Branford, CT 06405, USA.
De Lombaert
Stéphane
S
Brodbeck
Robbin
R
Gulianello
Michael
M
Chandrasekhar
Jayaraman
J
Horvath
Raymond F
RF
Ge
Ping
P
Kershaw
Mark T
MT
Krause
James E
JE
Kehne
John
J
Hoffman
Diane
D
Doller
Darío
D
Hodgetts
Kevin J
KJ
D001007:Anxiety / Q000188:drug therapy; D001665:Binding Sites; D020650:Combinatorial Chemistry Techniques; D003863:Depression / Q000188:drug therapy; D015195:Drug Design; D006801:Humans; D007546:Isoquinolines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D015394:Molecular Structure; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured; D000099052:CRF Receptor, Type 1
D007546:Isoquinolines; D018019:Receptors, Corticotropin-Releasing Hormone; D000099052:CRF Receptor, Type 1